SCHEDULE 13G/A: T. Rowe Price Amends Ascendis Pharma Stake to 4.8%

T. Rowe Price Investment Management, Inc. filed an amendment to its Schedule 13G, disclosing a 4.8% beneficial ownership in Ascendis Pharma A/S ADR.

Summary

• T. Rowe Price Investment Management, Inc. reported beneficial ownership of 2,667,563 American Depositary Receipts (ADRs) of Ascendis Pharma A/S.
• This ownership represents 4.8% of the class of securities.
• The reporting person holds sole voting power over 2,661,602 shares and sole dispositive power over 2,667,189 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G Amendment No. 2) and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or outlook.

Industry Context

This filing is a routine disclosure of an institutional investor's passive ownership stake, common in the pharmaceutical and biotechnology sectors where institutional holdings are prevalent.

Stakeholder Impact

• Shareholders are informed of the beneficial ownership stake held by a significant institutional investor, T. Rowe Price Investment Management, Inc.

Key Dates

Keywords

Ascendis Pharma, T. Rowe Price, Schedule 13G, ADR, beneficial ownership, institutional investor